Key Highlights
- The net loss was USD 26.4 million versus USD 22.5 million, and the nine-month net loss was USD 114.4 million.
- Cash, cash equivalents and investments totaled USD 403.8 million, sufficient to fund operations for at least twelve months.
- General and administrative expenses rose USD 1.5 million to USD 6.5 million from USD 5.0 million.
- Topline data from the Phase 2b BUOY-1 trial in major depressive disorder are anticipated in the first half of 2027.
Loss and Expenses
Seaport Therapeutics, Inc. (NASDAQ:SPTX) reported a third-quarter 2026 net loss of USD 26.4 million compared with USD 22.5 million a year earlier. The nine-month net loss was USD 114.4 million versus USD 50.7 million. General and administrative expenses were USD 6,454,000 versus USD 4,988,000, with employee compensation of USD 2.35 million, stock-based compensation of USD 1.50 million, professional fees of USD 1.38 million and facilities, depreciation, IT and other costs of USD 1.23 million.
Other income, net rose USD 1.1 million to USD 4.1 million from USD 3.0 million, and the income tax provision rose USD 32 thousand. The net loss rose about 17% in the quarter, general and administrative expense rose about 29%, employee compensation about 17%, stock-based compensation about 27% and professional fees about 39%. Other segment items, including interest income, net, Research and Development tax Credit and income tax provision, offset USD 3.95 million of the quarterly loss.
The company believes its existing cash, cash equivalents and investments of USD 403.8 million at September 30, 2026, which derive from its Series A and Series B financings, are sufficient to fund operations for at least twelve months from the date the financial statements were issued.
GlyphAllo Program
The company initiated the Phase 2b BUOY-1 trial in patients with major depressive disorder with or without anxious distress and anticipates topline data in the first half of 2027. In September 2026 it reported positive Phase 1 driving simulation data showing that evening dosing of GlyphAllo did not impair next-morning driving performance compared with placebo.
GlyphAgo and Early Programs
In April 2026 the company reported topline data from the single-ascending dose and crossover portions of its Phase 1 proof-of-concept trial for GlyphAgo. In October 2026 it dosed the first patient in a Phase 2a proof-of-pharmacology trial evaluating GlyphAgo on sleep and anxiety symptoms in generalized anxiety disorder with sleep disturbance, with topline data anticipated in early 2028. It plans to start a Phase 2/3 trial in generalized anxiety disorder in the first half of 2027, with topline data anticipated by the end of 2028.
The company is also advancing Glyph2BLSD, an oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in nonclinical studies for neuropsychiatric and headache disorders. Research and development costs for GlyphAgo decreased USD 0.8 million on lower nonclinical activity, partly offset by the start of the Phase 2a trial, and Glyph2BLSD costs decreased USD 0.1 million.
Clinical Milestones Ahead
The company cautioned that development timelines, probability of success and costs can differ materially from expectations. The Phase 2b readout remains the nearest scheduled milestone. Items to watch include BUOY-1 enrollment, the Phase 2/3 GlyphAgo start and spending against the cash balance.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...